WUXI APPTEC - [Overseas Regulatory Announcement - Corporate Governance Related Matters] — 2026032301059
WUXI APPTEC CO., LTD.*
Wuxi WuXi AppTec New Drug Development Co., Ltd.
(a joint stock limited company incorporated in the People's Republic of China)
(Stock code: 2359)
Overseas regulatory announcement
This overseas regulatory announcement is made by the Company in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
The full Chinese text of the following information published by the Company on the Shanghai Stock Exchange website is hereby provided for reference only.
By order of the board of directors
Wuxi WuXi AppTec New Drug Development Co., Ltd.
Chairman
Dr. Li Ge
Hong Kong, March 23, 2026
As of the date of this announcement, the Company's Board of Directors includes executive directors Dr. Li Ge, Dr. Chen Minzhang, Dr. Yang Qing and Mr. Zhang Zhaohui; non-executive directors Mr. Tong Xiaoyi and Dr. Wu Yibing; and independent non-executive directors Ms. Lu Shaohua, Dr. Yu Wei, Dr. Zhang Xin, Ms. Zhan Zhiling and Mr. Leng Xuesong.
*For identification only
Wuxi WuXi AppTec New Drug Development Co., Ltd. Internal Control Audit Report December 31, 2025
Internal Control Audit Report
Deshibao (review) No. (26) P03784
(Page 1 of 2) All shareholders of Wuxi WuXi AppTec New Drug Development Co., Ltd.:
In accordance with the relevant requirements of the "Audit Guidelines for Enterprise Internal Control" and the Chinese Certified Public Accountants Practice Standards, we audited the effectiveness of the internal control over the financial reporting of Wuxi WuXi AppTec New Drug Development Co., Ltd. (hereinafter referred to as "your company") on December 31, 2025.
- Enterprise’s Responsibility for Internal Control
In accordance with the provisions of the "Basic Standards for Enterprise Internal Control", "Guidelines for the Application of Enterprise Internal Control", and "Guidelines for the Evaluation of Enterprise Internal Control", it is the responsibility of your company's board of directors to establish, improve and effectively implement internal controls and evaluate their effectiveness.
- Responsibilities of Certified Public Accountants
Our responsibility is to express an audit opinion on the effectiveness of internal control over financial reporting based on the implementation of the audit work, and to disclose the significant deficiencies in internal control over non-financial reporting that we have noticed.
- Inherent limitations of internal control
Internal controls have inherent limitations and may fail to prevent and detect misstatements. In addition, since changes in circumstances may cause internal controls to become inappropriate, or the degree of compliance with control policies and procedures to be reduced, there is a certain risk in inferring the effectiveness of future internal controls based on the results of internal control audits.
Internal Control Audit Report - Continued
Deshibao (review) No. (26) P03784
(Page 2 of 2) IV. Audit opinions on internal control over financial reporting
We believe that your company maintained effective internal control over financial reporting in all material aspects in accordance with the "Basic Standards for Enterprise Internal Control" and relevant regulations as of December 31, 2025.
Deloitte Touche Tohmatsu Certified Public Accountants LLP (Special General Partnership) Chinese Certified Public Accountant: Mu Lanying China·Shanghai
Chinese Certified Public Accountant: Lin Qiumei
March 23, 2026